Vailshire Capital Management

Dr. Brian Price, the founder and managing member, is the sole portfolio manager. He is a board-certified cardiologist who continues to see patients while running the firm's concentrated equity portfolio. There is no investment committee; all position sizing, entry, and exit decisions are made by Price.

Vailshire invests exclusively in publicly traded equities. It does not make fund commitments, private company investments, or venture-stage allocations. The strategy relies on the liquidity of public markets while maintaining a private-equity-like holding period, often measured in years rather than quarters.

The firm targets mid-to-large-cap public companies with established commercial-stage products, though it will hold pre-revenue biotechnology companies when the clinical evidence and intellectual property profile meet its underwriting threshold. The strategy is stage-agnostic within public equities — the key filter is durability of competitive advantage, not market capitalization.

Deal flow originates from Price's clinical practice and medical network. As a practicing cardiologist, he evaluates medical devices, pharmaceuticals, and healthcare service models from a user's perspective before financial analysis begins. This clinical lens identifies adoption-curve signals that purely financial screens miss, particularly in interventional cardiology and cardiovascular drug development.

Most RIAs are financial-planning-centric firms that allocate client capital across third-party funds or model portfolios. Vailshire is a single-strategy equity manager where the investment decision-maker is also the subject-matter expert on the dominant sector held. The November 2023 decision to unwind the private fund and operate exclusively through separately managed accounts also distinguishes it, giving each client direct ownership of underlying securities with full tax-lot control.

The firm avoids commodity businesses, highly leveraged financials, and companies with undifferentiated products subject to pricing pressure. Within healthcare, it avoids single-asset binary biotech platforms with no pipeline depth and healthcare service models dependent on government reimbursement rates that lack pricing power. The manager also explicitly avoids businesses he cannot analyze through his clinical expertise — tempered by Berkshire Hathaway's circle-of-competence discipline.

The firm does not operate a philanthropic foundation or separate family office structure. Price's public commentary indicates that charitable giving is conducted personally, not through an institutional vehicle tied to the management company.